文献速递新发突发、热带与寄生虫病细菌感染、耐药与抗菌药物

吡喹酮治疗加蓬成人无症状恶性疟原虫感染的双盲安慰剂对照随机试验

Efficacy of Praziquantel for Treatment of Plasmodium falciparum Infection in Asymptomatic Gabonese Adults: A Double-Blind Placebo-Controlled Randomized Trial.
PubMed 文献 · J Infect Dis · 2026-01-01

吡喹酮组显微镜定原虫血症每小时下降高度显著(β=-0.006,P<.001),安慰剂组下降趋势不显著(β=-0.0013,P=.3);但第7天原虫清除率吡喹酮组9/22(41%)、安慰剂组6/22(27%)。结论认为吡喹酮有统计学显著抗疟活性,但效果较现行一线抗疟药温和。

要点

  • 吡喹酮40 mg/kg每日一次共3天可显著降低无症状恶性疟原虫血症,但7天清除率仅41%。
  • 安慰剂组7天原虫清除率为27%,吡喹酮组为41%,差异幅度有限。
  • 结果支持进一步研究吡喹酮与抗疟药联用在疟疾和血吸虫病共流行区的协同潜力。

核心结论

  • 吡喹酮对无症状恶性疟原虫血症具有统计学显著的抗疟活性,但效果相比现行一线抗疟治疗仅为中等。

研究设计与样本

  • 双盲、随机、安慰剂对照2b期试验在加蓬Lambaréné开展,纳入半免疫无症状恶性疟原虫血症成人。
  • 参与者按1:1随机接受安慰剂或吡喹酮40 mg/kg每日一次共3天,随访7天。

主要发现

  • 吡喹酮组显微镜定原虫血症log10转化后的每小时回归斜率为β=-0.006(P<.001),呈高度显著下降。
  • 安慰剂组相应回归斜率为β=-0.0013(P=.3),下降趋势不显著。
  • 第7天达到原虫清除者吡喹酮组为9/22(41%),安慰剂组为6/22(27%)。

临床怎么用

  • 吡喹酮单药抗疟效果有限,不宜替代现行一线抗疟治疗。
  • 在疟疾与血吸虫病共流行区,可关注吡喹酮与抗疟药联用的协同潜力,但需进一步研究。

局限性

  • 研究人群为半免疫无症状成人,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Schistosomiasis and malaria are major poverty-related parasitic infectious diseases. They are often coendemic and affect similar target populations. Mass drug administration and intermittent preventive treatment programs are commonly used for their control. From a programmatic perspective the establishment of preventive treatment programs targeting both diseases simultaneously would be a great advantage. While there is preliminary evidence that certain antimalarial drugs exert a clinically important effect on Schistosomes, little is known on whether praziquantel (PZQ), the only licensed drug to treat schistosomiasis, has activity against Plasmodium parasites. Therefore, the CORMA-MAL study was conducted to evaluate antimalarial activity of PZQ. METHODS: This double-blinded, randomized, placebo-controlled phase 2b trial was conducted in Lambaréné, Gabon and recruited semi-immune adults with an asymptomatic Plasmodium falciparum parasitemia. Participants were randomized (1:1) to receive placebo or 40 mg/kg PZQ once daily for 3 days and followed up for a total of 7 days. RESULTS: Forty-four participants were recruited. Analytical models indicated a highly significant hourly reduction of microscopically determined parasitemia in the PZQ arm and a nonsignificant decreasing trend in the placebo group (regression slopes of log10-transformed parasitemia: β=-0.006 [P < .001] and β=-0.0013 [P = .3], respectively). However, in total only 9 of 22 (41%) in the PZQ arm compared to 6 of 22 (27%) in the placebo arm reached parasite clearance by day 7. CONCLUSIONS: Findings demonstrate a statistically significant antimalarial activity of PZQ; however, the observed effect is only moderate compared to current first-line antimalarial treatments. Future research should investigate the synergistic potential of combining PZQ and antimalarial drugs in malaria and schistosomiasis control. Clinical Trials Registration.Pan African Clinical Trials Registry, PACTR202206584817951, 10 June 2022 (https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=22586).

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mischlinger J, Pechmann K, Werner J, et al. Efficacy of Praziquantel for Treatment of Plasmodium falciparum Infection in Asymptomatic Gabonese Adults: A Double-Blind Placebo-Controlled Randomized Trial. J Infect Dis. 2026. PMID: 41159886. doi:10.1093/infdis/jiaf544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。